Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
复制标题
DOI：
10.1002/lt.23394
复制
发表时间：
2012-04
影响因子：
4.6
通讯作者：
Cameron, Andrew M.
中科院分区：
文献类型：
--
作者：
Goldberg, David;French, Benjamin;Abt, Peter;Feng, Sandy;Cameron, Andrew M.
Candidates with hepatocellular carcinoma (HCC) within Milan criteria receive standardized Model for End-Stage Liver Disease (MELD) exception points due to the projected risk of tumor expansion beyond Milan criteria, meant to be equivalent to a 15% risk of 90-day mortality from listing, with additional points every 3 months, equivalent to a 10% increased mortality risk. We analyzed the United Network for Organ Sharing database from 1/1/05–5/31/09 to compare 90-day waitlist outcomes of HCC vs. non-HCC candidates with similar MELD scores. 259 (4.2%) HCC candidates initially listed with 22 MELD exception points were removed for death or clinical deterioration within 90 days of listing vs. 283 (11.0%) non-HCC candidates with initial laboratory MELD scores of 21–23. 93 (4.6%) HCC candidates with 25 exception points (after 3–6 months wait-time) were removed for death or clinical deterioration within 90 days vs. 805 (17.3%) non-HCC candidates with laboratory MELD scores of 24–26. 20 (3.0%) HCC candidates with 28 exception points (after 6–9 months wait-time) were removed for death or clinical deterioration within 90 days vs. 646 (23.6%) non-HCC candidates with laboratory MELD scores of 27–29. In multivariable logistic regression models, HCC candidates had a significantly lower 90-day odds of waitlist removal for death or clinical deterioration (P<0.001). Over time, the risk of waitlist removal for death or clinical deterioration was unchanged for HCC candidates (P=0.17), while it increased significantly for non-HCC candidates. The current allotment of HCC exception points should be reevaluated given the stable risk of waitlist dropout for these candidates.
登录
查看更多内容
融合了等待列表结果的例外和速率。
DOI：
10.1111/j.1600-6143.2011.03735.x
发表时间：
2011-11
期刊：
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子：
--
作者：
Massie AB;Caffo B;Gentry SE;Hall EC;Axelrod DA;Lentine KL;Schnitzler MA;Gheorghian A;Salvalaggio PR;Segev DL
通讯作者：
Segev DL
影响因子：
13.5
作者：
Berg, Carl L.;Merion, Robert M.;Shearon, Tempie H.;Olthoff, Kim M.;Brown, Robert S., Jr.;Baker, Talia B.;Everson, Gregory T.;Hong, Johnny C.;Terrault, Norah;Hayashi, Paul H.;Fisher, Robert A.;Everhart, James E.
通讯作者：
Everhart, James E.
影响因子：
4.6
作者：
Otto, Gerd;Herber, Sascha;Pitton, Michael
通讯作者：
Pitton, Michael
影响因子：
8.8
作者：
Washburn, K.;Edwards, E.;Freeman, R. B.
通讯作者：
Freeman, R. B.
影响因子：
2
作者：
French, Benjamin;Heagerty, Patrick J.
通讯作者：
Heagerty, Patrick J.